

## CURRICULUM VITAE

**Robert E. Dupuis, Pharm.D., FCCP**

### PERSONAL INFORMATION

---

**Address – Home:** 205 Kenilworth Place  
Chapel Hill, NC 27516

**Office:** Division of Pharmacotherapy & Experimental Therapeutics  
UNC Eshelman School of Pharmacy  
University of North Carolina at Chapel Hill  
CB# 7569, 3213 Kerr Hall  
Chapel Hill, North Carolina 27599-7569

**Contact:** (919) 966-6194; (919) 962-0644 FAX  
EMAIL: [re\\_dupuis@unc.edu](mailto:re_dupuis@unc.edu)

### EDUCATION

---

Doctor of Pharmacy  
State University of New York at Buffalo  
Buffalo, New York  
June 1982

Bachelor of Science in Pharmacy  
Northeastern University  
June 1979

### CERTIFICATION

---

Board Certification in Pharmacotherapy  
Board of Pharmaceutical Specialties  
May 1991 – December 2013

### LICENSURE

---

North Carolina (License number 09828)  
June 1985 - present

### PROFESSIONAL EMPLOYMENT

---

May 2013 – present	Clinical Professor of Pharmacy UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill
June 1995 – April 2103	Clinical Associate Professor of Pharmacy UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill
June 1995 – present	Clinical Specialist in Solid Organ Transplantation Department of Pharmacy UNC Hospitals

May 1989 – May 1995	Assistant Professor of Pharmacy School of Pharmacy University of North Carolina at Chapel Hill
June 1985 – May 1989	Instructor School of Pharmacy University of North Carolina at Chapel Hill
June 1984 – June 1985	Clinical Instructor School of Medicine State University of New York at Buffalo Buffalo, New York
July 1982 – June 1985	Clinical Coordinator in Medicine and Pharmacokinetics Buffalo General Hospital Buffalo, New York
October 1982 – June 1985	Clinical Instructor School of Pharmacy State University of New York at Buffalo Buffalo, New York
June 1979 – June 1980	Hospital Pharmacy Resident Moses Cone Memorial Hospital Greensboro, North Carolina

## **ADMINISTRATIVE POSITIONS**

---

2006 – present	Director of Clinical Research Fellowship Programs Division of Pharmacotherapy & Experimental Therapeutics UNC Eshelman School of Pharmacy
July 1986 – December 2010	Assistant Director of Toxicology Department of Laboratory Medicine UNC Hospitals
1996 – 2006	Director, Solid Organ Transplant Residency Program UNC Hospitals
June 1994 – September 1995 January 1986 – June 1991	Director, Clinical Pharmacokinetics Service UNC Hospitals

## **AWARDS AND HONORS**

---

White Coat Speaker 2013

"Instructor or Preceptor of the Year"

awarded by the UNC School of Pharmacy Pharm.D. classes: 1987, 1990, 1993, 1995, 1998, 2000, 2001, 2003, 2013, 2015

Fellowship in the American College of Clinical Pharmacy

awarded by the American College of Clinical Pharmacy, 2008

“Excellence in Teaching Award”  
awarded by the UNC School of Pharmacy, 2006, 2007

“Access Award”  
presented by Learning Disabilities Services, University of North Carolina at Chapel Hill, 2002

“Professional Accomplishment Award”  
presented by State University of New York at Buffalo School of Pharmacy, 1998

## MANUSCRIPTS AND REVIEWS

---

1. Persky AP, **Dupuis RE**. An eight year retrospective study in flipped pharmacokinetic courses. *Am J Pharm Educ* 2014;78:190
2. Moss MC, Kozlowski T, **Dupuis R**, Detwiler R, Lee RM, Deyo J. Lithium use for bipolar disorder post renal transplant: Is mood stabilization without toxicity possible? *Transplantation* 2014;97:23-24.
3. Everson GT, Hoefs JC, Niemann CU, Olthoff KM, **Dupuis R**, Lauriski S, Herman A, Milne N, Gillespie BW, Goodrich NP, Everhart JE. Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. *Liver Transplant* 2013;19:292-297
4. Guptil JT, **Dupuis RE**, D'Cruz O. Emerging sub-specialties in neurology: clinical development. *Neurology* 2013;80:14-7.
5. Winston DJ, 1263-301 Clinical Study Group. Efficacy and safety of maribavir dosing at 100mg twice daily for prevention of CMV disease in liver transplant recipients. A randomized double blind placebo controlled multicenter trial. *Am J Transplant* 2012;11:3021-3030.
6. **Dupuis R**, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. *Clinica Chimica Acta* 2012: Feb1 (Epub ahead of print).
7. Alloway RR, **Dupuis RE**, Garbardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA. Evolution of the Role of the Transplant Pharmacist on the Multidisciplinary Transplant Team. *Am J Transplantation* 2011;11:1576-83.
8. Eisenhart A, **Dupuis RE**. Pursuing a career in transplant pharmacy. *Am J Health Syst Pharm* 2008;65:2331-2333.
9. **Dupuis RE**, Stegall-Zanation J, Dupuis R, Persky AM. Experiences with case-based learning in clinical pharmacokinetics. *Am J Pharm Educ* 2008;72:29.
10. **Dupuis RE**, Persky AM, Use of Case-Based Learning in a Clinical Pharmacokinetics Course. *Am J Pharm Educ*. 2008 Apr 15;71(2):29.
11. **Dupuis R**, Harris M, Gillis K, Gerber D, Fair J. Experience with low dose valganciclovir prophylaxis in liver transplant recipients. *Transplant Proc* 2007;39:3266-70.
12. Persky AM, Stegall-Zanation J, **Dupuis RE**. Student perceptions of the incorporation of games into classroom instruction for basic and clinical pharmacokinetics. *Am J Pharm Educ* 2007;71:21.
13. Stern ST, Tallman MN, Miles KK, Ritter JK, **Dupuis RE**, Smith PC. Gender related differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats. *Drug Metab Dispos* 2007;35:449-54.
14. Naderer OJ, **Dupuis RE**, Heinzen E, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. *J Clin Pharmacol* 2005;45:219-226.
15. Johnson MW, **Dupuis RE**, Hollar K, Fair J. Limited dose daclizumab as induction immunosuppression in pediatric liver transplant recipients. *Ped Transplant* 2003;7:119.
16. Taber DJ, Malat GE, Fann AL, **Dupuis RE**. Prediction of vancomycin pharmacokinetics and creatinine clearance after liver transplantation. *Ther Drug Mon* 2003;25:67-72.
17. Taber DJ, Fann AL, Malat G, **Dupuis RE**. Evaluation of estimated and measured creatinine clearances for predicting the pharmacokinetics of vancomycin in adult liver transplant recipients. *Ther Drug Mon*

003 Feb;25(1):67-72.

18. Malat GE, **Dupuis RE**, Kassman B, Rhoads JM, Freeman K, Lichtman S, Johnson MW, Gerber D, Andreoni K, Fair J. Tacrolimus-induced pain syndrome in a pediatric orthotopic liver transplant patient. *Ped Transplant* 2002;6:435-438.
19. Taber DJ, **Dupuis RE**, Fann AL, Andreoni K, Gerber D, Fair J, Johnson MW, Shrestha R. Tacrolimus dosing requirements and concentrations in living donor liver transplant recipients. *Liver Transplantation* 2002;8:219-223.
20. Joy MS, Hollar KD, Neyhart CD, Hogan SL, **Dupuis RE**, Finn WF, Dooley MA. Assessment of risk factors for bone disease in renal transplant recipients. *J Pharm Tech* 2002;18:54-62.
21. **Dupuis RE**, Taber DJ, Fann AL, Lumbert KP. Medical management considerations for patients with lung transplantation. *J Pharm Pract* 2001;14:258-276.
22. Wiwattanawongsa K, Heinzen EL, Kemp DC, **Dupuis RE**, Smith PC. Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. *J Chromat B* 2001;763:35-45.
23. American College of Clinical Pharmacy Clinical Practice Affairs Committee. Practice guidelines for pharmacotherapy specialists. A position statement of the American College of Clinical Pharmacy. *Pharmacotherapy* 2000;20:487-490.
24. Taber D, **Dupuis RE**, Hollar KD, Stralzka AL, Johnson MW. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. *Transplant Proc* 2000;32:660-662.
25. Ciminelli A, **Dupuis RE**, Williams D, Hollar KD. The role of the pharmacist in a multidisciplinary patient education program on a renal transplant service. *Am J Health Sys Pharm* 2000;57:767-768.
26. **Dupuis RE**, Sredzienski ES. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. *Ther Drug Mon* 1999;21:161-165.
27. Hollar KD, Scott CS, **Dupuis RE**. Tobramycin Pharmacokinetics in a Pediatric Patient with Cystic Fibrosis Following Lung Transplantation. *J Ped Pharm Pract* 1998; 3:110-114.
28. Peckman HJ, **Dupuis RE**, Sawyer WT, Brouwer KLR, Cross RE. Vancomycin serum concentrations in patients with renal dysfunction: A comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. *Ther Drug Mon* 1996;18:647-53.
29. Wire PD, **Dupuis RE**, Lindley CL, Mohler DD, Bernard SO. Methotrexate disposition in a patient with an orthotopic neo-bladder with and without a urethral catheter cancer. *Pharmacotherapy* 1996;16:961-64.
30. **Dupuis RE**, Cooper A, Rosamond LJ, Campbell-Bright S. Delayed peak lithium concentrations in lithium overdose. *Ann Pharmacother* 1996;30:356-360.
31. **Dupuis RE**. Book review: Basic Clinical Pharmacokinetics. Third edition 1994. *Ann Pharmacotherapy* 1995;29:944.
32. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, **Dupuis RE**, Caiola SM. Appropriate use of heparin: empiric versus nomogram based dosing. *Arch Int Med* 1995;155:526-532.
33. Kirk JK, **Dupuis RE**. Therapeutic approaches to the treatment of hyperlipidemia in the transplant patient. *Ann Pharmacother* 1995;29:879-891.
34. Kirk JK, **Dupuis RE**, Miles M, Gaddy GD, Williams DM, Miranda JM. Salivary Theophylline Monitoring: Reassessment and Clinical Considerations. *Ther Drug Mon* 1994;16:58-66.

35. Price T, **Dupuis RE**, Carr B, Stanczyk F, Lobo R, Droegemueller W. Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. *Am J Obstet Gynecol* 1993;168:1400-6.
36. Miles MV, Miranda-Massari J, **Dupuis RE**, Mill MR, Zaritsky AL, Nocera M, Lawless ST. Determination of salivary digoxin with a dry strip immunometric assay. *Ther Drug Mon* 1992;14:249-54.
37. Miles MV, Zaritsky AL, Lawless St, Mill MR, Nocera MA, **Dupuis RE**. Digoxin monitoring in critically ill pediatric patients. American College of Clinical Pharmacology Meeting, *J Clin Pharmacol* 1991;31:851.
38. **Dupuis RE**, Miranda-Massari J. Anticonvulsants - Pharmacotherapeutic issues in the critically ill. *AACN Clinical Issues in Critical Care Nursing* 1991;2:639-656.
39. Roush MK, **Dupuis R**. Significance of the ciprofloxacin-antacid interaction. *DICP, Annals of Pharmacotherapy* 1991; 25:473-475.
40. **Dupuis R**, Lichtman S, Pollack G: Acute valproic acid overdose: Clinical course and pharmacokinetic disposition of valproic acid and metabolites. *Drug Safety and Adverse Drug Reactions* 1990;5:65-71.
41. **Dupuis R**, Matzke G, Maddux F, O'Neil M. Vancomycin disposition during continuous arteriovenous hemofiltration. *Clinical Pharmacy* 1989;8:371-374.
42. Tennison M, Miles MV, Pollack GM, Thorn MD, **Dupuis R**: Valproate metabolites and hepatotoxicity in an epileptic population. *Epilepsia* 1988; 29:543-547.
43. Pleasants R, Sawyer W, **Dupuis R**: Alterations in population volume of distribution values for aminoglycosides. *Clin Pharm* 1986;5:872-873.
44. **Dupuis R**, Slaughter R: Severe theophylline toxicity. *Am J Med* 1985;A76-A82.

## BOOK CHAPTERS

---

1. Taber DJ, **Dupuis RE**. "Solid Organ Transplantation" in *Applied Therapeutics: The Clinical Use of Drugs*, 10<sup>th</sup> edition. Lippincott Williams & Wilkins, 2012.
2. **Dupuis RE**. "Pharmacotherapy of Renal Failure" in *PharmPrep. Guide to NaPlex*, 4<sup>th</sup> edition. ASHP Publications, 2010.
3. Taber DJ, **Dupuis RE**. "Kidney & Liver Transplantation" in *Applied Therapeutics: The Clinical Use of Drugs*, 9<sup>th</sup> edition. Lippincott Williams & Wilkins, 2008.
4. **Dupuis RE**. "Pharmacotherapy of Renal Failure" in *PharmPrep. Guide to NaPlex*, 3<sup>rd</sup> edition. ASHP Publications, 2007.
5. Taber DJ, **Dupuis RE**. "Solid Organ Transplantation" in *Applied Therapeutics: The Clinical Use of Drugs*, 8<sup>th</sup> edition. Lippincott Williams & Wilkins, 2004.
6. **Dupuis RE**. "Medical Management of Lung Transplant Recipients" in *Respiratory Pharmacotherapy Reference Guide*, 1<sup>st</sup> edition. 2004.
7. **Dupuis RE**. "Solid Organ Transplantation" in *Applied Therapeutics: The Clinical Use of Drugs*, 7<sup>th</sup> edition. Lippincott Williams & Wilkins, 2001.
8. **Dupuis RE**. "Solid Organ Transplantation" in *Applied Therapeutics: The Clinical Use of Drugs*, 6<sup>th</sup>

edition. Lippincott Williams & Wilkins, 1995.

9. **Dupuis RE**, Miranda-Massari J. "Dialysis and Renal Transplantation" in *Workbook for Clinical Pharmacy and Therapeutics*. William and Wilkins, 1992.
10. Matzke GR, **Dupuis RE**, Frye RF, Luke DR. "Renal Transplant Therapy and Dialysis" in *Clinical Pharmacy and Therapeutics*, 5<sup>th</sup> edition. William and Wilkins, 1992.
11. **Dupuis RE**. "Bayesian forecasting, pharmacokinetics and therapeutic drug monitoring" in *Yearbook of Pathology and Clinical Pathology*. Brinkhous KM, Dalldorf FG, Langdell RD, McLendon WW (eds.), 1991.
12. **Dupuis R**. "Drug Interactions" in *Pharmacotherapeutics: Nursing Practice in Progress*, M. Matheson (ed.), 1984.

## SCIENTIFIC ABSTRACTS

---

1. Moss M, **Dupuis R**, Deyo J, Deyo J, Kozlowski T, Lee R. Use of erythropoietin stimulating agents for treatment of anemia in the early post transplant period. *Am J Transplant* 2014;14:1286.
2. Huang J,, Wheeler M,, Lee R, Zeynep T, **Dupuis R**, Kozolwski T. Does length of hospital stay and hospital-wide incidence incidence have an impact on C Difficile (CDI) in organ transplant recipients. *Am J Transplant* 2013;13:343.
3. Wheeler M, Deyo J, Huang J, Lee R, Kozlowski T, **Dupuis RE**. Incidence, risk factors, response rate in initial therapy for C Difficile in solid organ transplants. *Am J Transplant* 2013;13:344.
4. Moss M, **Dupuis RE**, Deyo J, Kozlowski T, Chhay A, Lee RA. Impact of thymoglobulin dosing: is the current approach successfully treating acute cellular rejection in kidney allografts. *Pharmacotherapy* 2013;33:269.
5. Roshdy D, Baker C, **Dupuis R**, Deyo J, Analysis of dosing strategies for secondary prophylaxis for prevention of CMV recurrence in solid organ transplantation. *Pharmacotherapy* 2013;13:270.
6. Deyo JC, **Dupuis R**, Lee RA, Kozlowski T. Modification of induction in kidney transplants with pre-transplant viral infection or chronic long term immunosuppression. *Pharmacotherapy* 2012;32:272-3.
7. Nguyen T, **Dupuis RE**, Deyo J, Lee RA, Kozlowski T, Gerber D. The utilization of mycophenolate concentrations in kidney and liver transplant recipients in a tertiary hospital. *Am J Transplant* 2012;12 (suppl 3):206.
8. Everson Gt, Hoefs JC, Niemann CL, Olthoff KM, **Dupuis R**. Functional elements associated with hepatic regeneration in living donors after right lobectomy – a sub-study of the adult to adult living donor liver transplantation cohort (A2ALL) study. *Hepatology* 2010;4(Suppl):569A.
9. Tallman MN, Ali SY, Gillis KA, **Dupuis RE**, Miles KK, Ritter J, Smith P. Variability in human UDP-GT protein expression and activity in duodenum, jejunum, and colon. *Drug Metab Rev* 2005;37(suppl 2).
10. Stern ST, Tallman MN, Miles KK, **Dupuis RE**, Ritter J, Smith P. Gender related differences in mycophenolate mofetil induced GI toxicity in rats. *Drug Metab Rev* 2005;37(Suppl2).
11. **Dupuis RE**, VanBeuge D, Conoley R. Effectiveness of low dose valganciclovir in liver transplant recipients. *Am J Transplant* 2005;4.

12. Johnson M, Salm J, Mciver P, **Dupuis RE**. Comparative analysis of delayed tacrolimus immunosuppression +/- antibody induction in orthotopic liver transplant patients with pre-operative renal dysfunction. *Am J Transplant* 2004;4.
13. Johnson M, Zacks S, Mclver P, Russo M, **Dupuis RE**. Randomized trial of oral ganciclovir plus CMV immunoglobulin versus oral ganciclovir alone for CMV prophylaxis in liver and kidney transplant recipients *Am J Transplant* 2004;4.
14. Conoley R, **Dupuis R**, Fair J. The safety and efficacy of rVIIa in orthotopic liver transplantation. *Am J Transplant* 2004;4.
15. Conoley R, **Dupuis R**, Fair J. The safety and efficacy of rVIIa in orthotopic liver transplantation. *Pharmacotherapy* 2004;24.
16. **Dupuis RE**, Williams EE, Hawke RI. CYP450 activity and the acute phase response in healthy donors after living-donor liver transplantation. *Hepatology* 2004;40(Suppl 4):561A.
17. Kassman B, Summers K, Johnson M, Conoley R, **Dupuis RE**. Sirolimus use in pediatric liver transplant recipients. With graft rejection or calcineurin-induced toxicity. *Ped Transplant* 2004;7:113.
18. Reid C, **Dupuis RE**, Fann AL, Taber DJ, Johnson MW, Fair J. Evaluation of calcium and vitamin D supplementation in liver transplant recipients. *Am J Transplant* 2001;1:421.
19. Thompson T, Zacks S, Salm J, Hollar K. **Dupuis RE**, Johnson M. Is CMV infection risk factor for FSGS in renal transplant recipients. *Transplantation* 200;69:s216.
20. Taber DJ, **Dupuis RE**, Hollar KD, et al. Comparison of CMV prophylaxis and preemptive therapy in liver and kidney transplant recipients. *Transplantation* 2000;69:s181.
21. Hollar KD, Zacks SL, **Dupuis RE**, et al. Prevalence of low bone mass and risk factors in patients awaiting liver transplantation. *Transplantation* 2000;69:s316.
22. Johnson MW, Salm J, Taber D, Schoots M, Hollar KD, **Dupuis RE**. Delayed use of tacrolimus in orthotopic liver transplant patients with renal insufficiency. *Transplantation* 2000;69:s216.
23. Wiwattanawongsa K, Heinzen EL, **Dupuis RE**, Smith PC. Influence of antibiotics on the disposition of mycophenolic acid in the guinea pig. *AAPS* 1999;s420.
24. Naderer OJ, **Dupuis RE**, Wiwattanawongsa K, Campbell BJ, Hege SG, Smith PC, Johnson MW. Reduction of plasma mycophenolic acid and its glucuronide concentrations with antibiotic treatment. *Clin Pharmacol Ther* 1999;65:159.
25. Hollar KD, **Dupuis RE**, Williams DW, Dennis BE, Joy MS. Corticosteroid-induced osteoporosis: assessment of potential risk and prescribed treatment in organ transplant recipients and patients with pulmonary disease. *Int Pharm Abstr* 1998.
26. Joy MS, Hollar KD, Neyhard CD, Dooley MA, Hogan SL, **Dupuis, RE**, Finn WF. Risk factors for steroid induced bone disease in renal transplantation. *Transplantation* 1998; 65:150.
27. Smith A, **Dupuis R**, Gott K. Conversion from Sandimmune to Neoral in stable lung transplant recipients. *Pharmacotherapy* 1997;17:202.
28. Lee B, **Dupuis R**, Gott K, Paradowski L, Aris R, Detterbeck F, Egan T. The effect of conversion from Sandimmune to Neoral on the pharmacokinetics of cyclosporine in lung transplant recipients with cystic fibrosis receiving chronic ketoconazole. *Pharmacotherapy* 1996;16:516-7.



29. Johnson M, Odell P, **Dupuis R**, Bunzendahl H, Fair J. The cost effectiveness of conversion of Sandimmune to Neoral in liver transplant recipients. American Society of Transplant Physicians, Dallas, TX, May 1996;18:647.
30. **Dupuis RE**, Sofowora OO, Finn WF. Prediction of cyclosporine area under the concentration-time curve using limited sampling strategies. *Pharmacotherapy* 1994;14:372.
31. Baldwin JE, **Dupuis RE**, Wire PD. Cyclosporine clearance in patients with and without cystic fibrosis following lung transplantation. *Int Pharm Abst* 1994;31:2288.
32. **Dupuis RE**, Wire PD, Sredzienski ES. Tobramycin pharmacokinetics and dosing requirements in patients with cystic fibrosis preceding and following lung transplantation. *Int Pharm Abst* 1994;31:2291.
33. Miles MV, **Dupuis RE**, Miranda-Massari JR, Soucie MP. Digibind interference with FPIA and ELIA digoxin methods. 3rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Philadelphia, PA, May, 1993.
34. Miranda-Massari JR, Miles MV, Soucie MJ, **Dupuis RE**. Comparison of digibind effects of digoxin concentrations with FPIA and ELIA methods. 21st American College of Clinical Pharmacology Meeting, September 1992. *J Clin Pharmacol* 1992;32:755.
35. Kirk JK, **Dupuis RE**, Miles MV, Miranda JR, Williams DM. Relationship between saliva and serum theophylline concentrations: A comparison of two assays and two saliva stimulation methods. Twenty-first Annual American College of Clinical Pharmacology Meeting. September 1992. *J Clin Pharmacol* 1992;32:754.
36. Breyer ED, **Dupuis RE**, Cross RE, Letzow CB, Chapman JF. Development and evaluation of an optimized HPLC assay for cyclosporine A (CsA) and two major metabolites. American Association of Clinical Chemists Meeting, July 1992. *Clin Chem* 1992;38:1003.
37. Breyer ED, **Dupuis RE**, Cross RE, Miranda JR, Chapman JF. Comparison between three types of specific whole blood cyclosporine A assays. American Association of Clinical Chemists Meeting, July 1992. *Clin Chem* 1992;38:1003.
38. Kirk JK, **Dupuis RE**, Miles MV, Williams DM, Miranda JM. Comparison of a dry reagent method with fluorescence polarization immunoassay for the determination of salivary theophylline concentrations. American College of Clinical Pharmacy Meeting, August 1992. *Pharmacotherapy* 1992;12:248.
39. Price T, **Dupuis RE**, Carr B, Stanczyk F, Lobo R, Droegemueller W. Multiple dose pharmacokinetics of a 35 ug ethinyl estradiol, 1 mg norethindrone oral contraceptive in women with chronic renal failure on peritoneal dialysis. Society for Gynecologic Investigation Meeting, March 1992.
40. Matzke GR, Frye RF, **Dupuis RE**, Carson SW. Optimization of vancomycin bayesian analysis: Initial population parameters (IPP) vs Forecasting Program. 12th Annual ACCP Meeting, Minneapolis, MN, August 1991. *Pharmacotherapy* 1991;11:267.
41. **Dupuis RE**, Miranda-Massari JR, Miles MV, Soucie M. Serial serum digoxin concentrations in patients receiving digoxin specific FAB fragments (Digibind): A comparison between FPIA and IMAT. 22nd Annual Southeastern Conference for Postgraduate Pharmacy Education and Training, Athens, GA, April 1991.
42. Price T, **Dupuis RE**, Pollack G, Mattern W, Stanczyk F, Lobo R, Dotters D, Droegemueller W. Single dose pharmacokinetics of a 35ug ethinyl estradiol, 1mg norethindrone combination oral contraceptive in women with chronic renal failure on CAPD. Society of Gynecologic Investigation Meeting, Dallas, TX, March 1990.
43. Manning J, Hak L, **Dupuis R**, Dukes G, Gilligan P. Effect of calcium & urea in peritoneal dialysis fluid

on the in vitro killing of *Pseudomonas aeruginosa* by tobramycin. ASHP Midyear, Atlanta, GA, December 1989.

44. Hak LJ, Sawyer WT, Pleasants RP, **Dupuis RE**, Sarver PJ. Relationship between aminoglycoside dose, serum concentration and changes in serum creatinine over time during routine therapy in a university hospital. American College of Clinical Pharmacy, August 1989. *Pharmacotherapy* 1989;9:189.
45. Howlet CM, Miles M, Cross R, Tennison M, Greenwood R, **Dupuis R**. Serum N-desmethylmethsuximide determination using a modified ethosuximide assay procedure. American Association of Clinical Chemists Meeting, July 1988. *Clin Chem* 1988;34:1255.
46. **Dupuis R**, Matzke G, Maddux F, O'Neil M: Vancomycin disposition during continuous arteriovenous hemofiltration. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. *Inpharma* 1989;26:543.
47. Pleasants R, **Dupuis R**, Sawyer W: Determination of tobramycin pharmacokinetic parameters by three immunoassays. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. *Inpharma* 1989;26:546.
48. Tennison M, Miles MV, Pollack GM, **Dupuis R**: Valproic acid metabolites and hepatotoxicity in an epileptic population. American Epilepsy Society Meeting Proceedings, December 1987. *Epilepsia* 1987;28:627.
49. **Dupuis R**, Pleasants R, Williams D, Calmes H: Use of a Bayesian program to predict serum theophylline concentrations in the critically ill patient. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1986.

## OTHER PUBLICATIONS

---

1. Maldonada AQ, Tichy EM, Rogers CC, Campara M, et al. Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation. *Am J Health-Sys Pharm* 2015;72:e39-e51. Served as contributing reviewer
2. Mueller EW, Bishop JR, Kannan AO, Kiser YH, et al. ACCP Commentary: Research Fellowship Programs as a Pathway for Training Independent Clinical Pharmacy Scientists. Served as contributing reviewer
3. **Dupuis R**. Drug interactions with cyclosporine. *NCSHP Newsletter*, January 1991.
4. **Dupuis R**. Drug interference with serum creatinine measurements. *NCSHP Newsletter*, February 1990.

## PRESENTATIONS

---

1. *Nutritional Vitamin D in Chronic Kidney Disease*  
Triangle College of Clinical Pharmacy  
Durham, NC  
November 2012
2. *The Science, the Art, and the Allure of Transplantation: Student Program*

American Transplant Congress Annual Meeting  
Boston, MA  
June 2012

3. *Pharmacokinetic and Drug Interaction Profile of Newer Agents in Hepatitis C*  
Abbott Laboratories AASLD Transplant Advisory Meeting  
Boston, MA  
November 2010
4. *Immunosuppression in Solid Organ Transplantation*  
International Transplant Nurses Society 7<sup>th</sup> Annual Symposium  
Chapel Hill, NC  
2010
5. *Bioequivalence Issues in Transplantation*  
Triangle Transplant Meeting  
Chapel Hill, NC  
February 2009
6. *Drug Therapy Challenges in Solid Organ Transplantation*  
American Association of Pharmacy Technicians National Convention  
Raleigh, NC  
August 2008
7. *Transplant Pharmacology: Evolving Issues in Solid Organ Transplant*  
International Transplant Nurses Society 5<sup>th</sup> Annual Conference  
Chapel Hill, NC  
March 2008
8. *Transplant Recipient Education Initiatives: Current Perspectives in Transplant Therapy*  
Astellas Pharmacy National Advisory Meeting  
Chicago, IL  
July 2007
9. *Current Immunosuppressive Therapy: Current Practice and Trends in Organ Transplantation*  
UNC School of Nursing Annual Meeting  
Chapel Hill, NC  
March 2007
10. *Post- Transplant Management of Hepatitis B in Liver Transplant Recipients*  
Nabi Pharmaceuticals Advisory Board Meeting  
Baltimore, MD  
September 2006
11. *Future of Transplant Pharmacy Training Programs*  
National Meeting of Transplant Pharmacy Preceptors  
Boston, MA  
July 2006
12. *Acute Phase Response and Hepatic Drug Metabolism Activity and Recovery After Living-Donor Liver Transplantation*  
UNC DPET Seminar Series  
January 2006
13. *Role of Mycophenolic Acid in Kidney Transplantation*  
UNC Division of Nephrology Transplant Fellows Conference  
Chapel Hill, NC

October 2005

14. *Hepatitis B and C Post-Liver Transplant: Prophylaxis and Treatment Options*  
National Transplant Coordinators Advisory Board Meeting  
Chicago, IL  
August 2005
15. *Update on Therapeutic Drug Monitoring of Immunosuppressives in Organ Transplantation*  
Transplant Education Conference Piedmont Hospital  
Atlanta, GA  
July, 2005
16. *Induction, Infection after Liver Transplantation*  
Transplant Seminar, Emory University Hospital  
Atlanta, GA  
July 2005
17. *Complications of Immunosuppression: Cutting Edge: Advances in Organ Transplantation*  
UNC School Of Nursing  
Chapel Hill, NC  
April 2005
18. *Assessment of Hepatic CYP450 Activity During Liver Regeneration Following Living-Donor Liver Transplantation*  
Colorado Springs, CO  
June 2004
19. *Immunology- An Almost New Frontier in Drug Therapy*  
North Carolina Association of Pharmacists Annual Convention/Carolina Seminar  
Research Triangle Park, NC  
October, 2003
20. *New Treatment Approach to Hepatitis C*  
NCAP Acute Care Practice Forum  
Greensboro, NC  
April 2003
21. *Long Term Complications of Hyperlipidemia in Solid Organ Transplant Recipients*  
ACCP Annual Meeting  
Albuquerque, NM  
October 2002
22. *Update on Immunosuppression in Renal Transplantation*  
UNC School of Medicine Nephrology Conference  
Chapel Hill, NC  
June and August 2002
23. *Influence of Liver Regeneration on Drug Metabolism after Living Donor Liver Transplantation*  
Whistler, BC, Canada,  
March 2002
24. *Living Donor Liver Transplantation and Impact on Drug Therapy*  
UNC School of Medicine, GI & Hepatology Conference  
Chapel Hill, NC  
March 2002
25. *Important Issues and Medical Management of Complications in Transplant Recipients*

ACCP Annual Meeting  
Tampa, FL  
October 2001

26. *The Role of Pharmacokinetics in the Management of Immunosuppressives in Organ Transplantation*  
Fujisawa Regional Meeting  
Chapel Hill, NC  
June 2001
27. *Overview of Immunosuppressive Protocols in Organ Transplant Recipients*  
Role of the Pharmacist  
Marco Island, FL  
January 2001
28. *Cardiovascular Risks Factors: The Role of New Immunosuppressants*  
ACCP Annual Meeting  
Los Angeles, CA  
November 2000
29. *The Role of the Transplant Pharmacist*  
Carolinas Medical Center  
Charlotte, NC  
October 1999
30. *The New Immunosuppressives in Solid Organ Transplant*  
UNC Transplant Symposium  
Chapel Hill, NC  
September 1999
31. *Cyclosporine: Pharmacokinetics & Generic Substitution*  
UNC Comprehensive Transplant Center's Kidney Transplant Seminar  
Chapel Hill, NC  
August 1999
32. *Long Term Complications of Solid Organ Transplant Recipients*  
American Society of Health Systems Pharmacists Annual Meeting  
Reno, Nevada  
June 1999
33. *Update: Pharmacotherapy in Solid Organ Transplantation*  
University of North Carolina  
Chapel Hill, NC  
November 1996
34. *Cyclosporine: The Old and New*  
Duke University Medical Center, Department of Pharmacy Conference  
Durham, NC  
May 1996
35. *Pharmacotherapy in Kidney Transplantation*  
UNC Ambulatory Care Pharmacy Conference  
May 1996
36. *Drug Interactions Update*  
Area Health Education Center Continuing Education Program  
Fayetteville, NC

February 1996

37. *Pharmacotherapy in the Elderly*  
Area Health Education Center Continuing Education Program  
Burlington, NC  
November 1995
38. *Tacrolimus*  
Transplant Recipients International Organization  
Cary, NC  
November 1995
39. *Medicine After Lung Transplantation*  
UNC Lung Transplant Support Group  
Chapel Hill, NC  
Spring 1996 and Fall 1995
40. *Clinical Pearl: Cystic Fibrosis and the Lung Transplant*  
American Society of Hospital Pharmacists Midyear Meeting  
Miami, FL  
December 1994
41. *Food and Drug Interactions*  
Ninth Annual Pharmacy Practice Seminar, UNC School of Pharmacy  
Wilmington, NC  
September 1994
42. *Therapeutic Drug Monitoring*  
Eighth annual Pharmacy Practice Seminar, UNC School of Pharmacy  
Wilmington, NC  
September 1993
43. *Encounters in Solid Organ Transplantation*  
TCCP  
Research Triangle Park, NC  
September 1993
44. *Pharmacokinetics in the Critically Ill*  
Duke University Infectious Disease Update  
Wilmington, NC  
September 1993
45. *Ten Years of Cyclosporine in Transplantation*  
Virginia Medical Society Continuing Education Program  
Danville, VA  
April 1993
46. *Immunosuppressives in Heart Transplantation*  
UNC Hospitals Department of Nursing Program  
Chapel Hill, NC  
November 1992
47. *Renal Failure Workshop*  
Seventh Annual Pharmacy Practice Seminar  
UNC School of Pharmacy and North Carolina Pharmaceutical Association  
Wilmington, NC  
September 1992

48. *Pharmacokinetics and Plasmapheresis*  
Miles Medical Supervisors Meeting, Miles Inc.  
Raleigh, NC  
August 1992
49. *Pharmacokinetic Considerations in Special Populations*  
Pediatrics and Geriatrics  
Glaxo Clinical Pharmaceutical Scientist Curriculum Program, Glaxo Inc.  
Chapel Hill, NC  
May 1992
50. *Organ Transplantation Update: Pharmacology of Immunosuppression*  
UNC Hospitals Department of Nursing CE Program  
Chapel Hill, NC  
March 1992
51. *Therapeutic Use of Monoclonal Antibodies*  
Glaxo Clinical Pharmaceutical Scientist Curriculum Program  
Chapel Hill, NC  
January 1992
52. *Inter and Intrasubject Variability in the Pharmacokinetics of Cyclosporine in Renal Transplants at UNC: Preliminary Analysis*  
Department of Medicine, Division of Nephrology, UNC  
Chapel Hill, NC  
October 1991
53. *Immunosuppressant Therapy in Transplant Patients*  
Sixth Annual Pharmacy Practice Seminar, UNC  
School of Pharmacy and North Carolina Pharmaceutical Association  
Wilmington, NC  
September 1991
54. *Immunosuppressives in Adult Liver Transplantation*  
UNC Hospitals Department of Nursing CE Program  
Chapel Hill, NC  
September 1991
55. *Immunosuppressives in Pediatric Liver Transplantation*  
UNC Hospitals Department of Nursing CE Program  
Chapel Hill, NC  
June, July, August 1991
56. *Pharmacokinetics and Pharmacodynamic Changes in the Elderly*  
Northwest AHEC, Appalachian Geriatric Education Center  
May 1991
57. *Lung Transplantation and the Role of Immunosuppressive Agents*  
UNC Department of Nursing CE Program  
Chapel Hill, NC  
February 1991
58. *Immunosuppression in Heart Transplantation*  
UNC Department of Nursing CE Program  
Chapel Hill, NC  
January 1991

59. *Bayesian Forecasting and Therapeutic Drug Monitoring*  
UNC Clinical Pathology Series  
Chapel Hill, NC  
June 1990
60. *Principles of Antimicrobial Therapy IV: Aminoglycosides and Quinolones*  
Wake AHEC  
Raleigh, NC  
May 1990
61. *Antilymphocyte Antibodies (OKT3) in Transplantation*  
NCSHP Winter Meeting  
High Point, NC  
February 1990
62. *Antibiotic Drug Dosing in Renal Impairment*  
Roerig Teleconference  
Chapel Hill, NC  
November 1989
63. *Immunosuppressives in Organ Transplantation*  
American Association of Critical Care Nursing  
Durham, NC  
November 1989
64. *New Approach to Cyclosporine Monitoring & Dosing in Renal Transplants*  
Nephrology Conference, UNC Hospitals  
Chapel Hill, NC  
October 1989
65. *Immunosuppressives in Heart Transplantation*  
UNC Department of Nursing CE Program  
Chapel Hill, NC  
October 1989
66. *Comparison of Assay Methodologies for Measuring Cyclosporine*  
Department of Medicine, Division of Nephrology, UNC  
Chapel Hill, NC  
March 1989
67. *Immunosuppressives in Cardiac Transplantation*  
Department of Nursing, NCMH, CE Program  
January 1989
68. *Vancomycin Dosing in Critically Ill Patients*  
Critical Care Grand Rounds, Department of Medicine, UNC  
Chapel Hill, NC  
November 1988
69. *The Value of Clinical Pharmacokinetic Services*  
Annual Meeting of the NC American Association of Clinical Chemists (AACC)  
Chapel Hill, NC  
September 1988
70. *Evaluation of Aminoglycoside Pharmacokinetic Software*  
Area Health Education Center (AHEC) Continuing Education (CE) Program



Rocky Mount, NC  
November 1987

71. *Pharmacokinetics of Vancomycin and Aminoglycosides*  
NCMH Department of Laboratory Medicine Continuing Education Program  
October 1987
72. *The Value of Vancomycin Serum Concentrations*  
NCSHP Annual Fall Meeting  
Raleigh, NC  
October 1987
73. *New Advances in Drug Therapy*  
NCSHP Meeting  
Greensboro, NC  
September 1987
74. *Role of an Active Metabolite in Therapeutic Drug Monitoring*  
Pharmacy Grand Rounds, NCMH  
April 1987
75. *Pentamidine - An Overview*  
Pharmacy Grand Rounds, NCMH  
March 1987
76. *Pharmacokinetic Software - the Abbott System*  
Seminar on Microcomputers, Drug Information and Statistics, NCSHP Meeting  
Greenville, NC  
November 1986
77. *Blood Collection in Therapeutic Drug Monitoring*  
North Carolina Society of Hospital Pharmacists (NCSHP) Annual Meeting  
Clinical Pearls Session  
Greensboro, NC  
October 1986
78. *The Role of Digoxin Antibody in the Treatment of Digoxin Toxicity*  
Pharmacy Grand Rounds, NCMH  
September 1986
79. *Therapeutic Drug Monitoring*  
Clinical Pharmacology Conference, Department of Medicine, UNC  
Chapel Hill, NC  
October 1985
80. *Theophylline: An Update*  
Pulmonary Grand Rounds, Department of Medicine, UNC  
Chapel Hill, NC  
October 1985

## **RESEARCH GRANTS AND AWARDS**

---

1. Co-Investigator. Restoration of Hepatic Function in Living Liver Donors: An A-2All Multicenter Ancillary Study. National Institutes of Health. 2005 – 2010. \$250,000.

2. Co-Investigator. Adult to Adult Living Donor Liver Transplantation. National Institutes of Health. 2002 – 2009. \$842,000.
3. Principal Investigator. An In Vivo Assessment of Changes in CYP450 Activities During Liver Regeneration Following Living Donor Liver Transplantation. UNC University Research Grant. 2005 – 2007 \$3,720.
4. Principal Investigator. Determination of Cytochrome P450 Activities During Liver Regeneration in Donors and Recipients Following Living Donor Liver Transplantation. Fujisawa Pharmacy Grant. 2002 – 2005. \$20,000.
5. Co-Investigator. The Role of UGTs in Drug Disposition. National Institutes of Health. 2002 – 2006. \$875,000.
6. Co-Investigator. Botanical Drug Interactions in HIV: Impact in Glucuronidation. National Center for Complementary and Alternative Medicine. 2004 – 2006. \$250,000.
7. Principal Investigator. The Role of Intestinal UGTs in Drug Disposition. UNC School of Pharmacy Seed Grant. 2000. \$5,750.
8. Principal Investigator. Time Dependent Changes in the Pharmacokinetic and Pharmacodynamics of Morphine and Metabolites in Patients with Trauma and Burn Injuries. UNC Injury Prevention Research Center Grant. 1994. \$6,000.
9. Co-Principal Investigator. A Comparative Study of the Pharmacokinetics of Morphine and Its Metabolites in Patients with End-Stage Renal Disease and In Normal Volunteers. UNC School of Pharmacy Faculty Seed Grant. 1993. \$6,000.
10. Principal Investigator. Impact of a Novel Pharmacokinetic Dosing Model for Cyclosporine on Patient Outcome and Costs in Renal Transplant Patients. ASHP Research and Education Foundation Demonstration Grant. 1989 – 1991. \$4,900.
11. Principal Investigator. Pharmacokinetic Profiling of Cyclosporine in Renal Transplant Patients. North Carolina Memorial Hospital Innovative Research Grant. 1989 – 1991. \$35,000.
12. Co-Principal Investigator, Impact of Computerized Pharmacokinetic Forecasting on Practitioner Competency, Kinetic Consultation Activity and Patient Outcome. ASHP Research and Education Foundation Demonstration Grant. 1990 – 1992. \$4,900.
13. Principal Investigator, Pharmacokinetic Modeling of Cyclosporine and Role of Metabolites in Renal Transplantation. UNC Junior Faculty Development Award. 1990 – 1991.

## **RESEARCH CONTRACTS**

---

1. Co-Principal Investigator. A Multicenter Randomized Double-blind Placebo Controlled Multiple Dose Study of the Safety Tolerability and Population of Pharmacokinetics of CMX001 in Post-transplant Subjects with BK Virus Viruria. Chimerix INC. 2008 – 2011. \$75,900.
2. Principal Investigator. A Randomized Double-blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants. ViroPharma INC. 2007 – 2009. \$87,000.
3. Principal Investigator. The Pharmacokinetics of Mycophenolate in CF and non-CF Lung Transplant Recipients. Roche. 1998. \$28,300.
4. Principal Investigator. Pharmacokinetics and Pharmacodynamics of Mycophenolate in Liver Transplant Recipients. Roche. 1998. \$45,700.

5. Principal Investigator. The Influence of Antibiotics on the Enterohepatic Recirculation of Mycophenolate Mofetil. UNC Faculty Seed Grant. 1997. \$3,200.
6. Co-investigator. Comparison of CMV IVIG and Oral Ganciclovir Versus Oral Ganciclovir Alone for Prophylaxis in Kidney and Liver Transplant Recipients. MedImmune, Inc. 1997.
7. Principal Investigator. The Pharmacokinetics of Cyclosporine Before and After Conversion of Neoral from Sandimmune in Lung Transplant Recipients With Cystic Fibrosis. Sandoz Pharmaceutical Corporation. 1995. \$3,000.
8. Principal Investigator. Survey of Transplant Recipient-Pharmacist Interactions, Sandoz Pharmaceutical Corporation. 1994. \$500.
9. Principal Investigator, Comparison of a Dry Reagent Method with Fluorescence Polarization Immunoassay for the Determination of Salivary and Serum Theophylline Concentrations. Miles Inc. 1992. \$4,600.
10. Principal Investigator. Evaluation of Two Immunoassays for the Determination of Salivary and Serum Digoxin Concentrations in Patients with Renal Failure. Miles Inc. 1992. \$5,000.
11. Co-Investigator. Bioavailability Study of Rifampin Suspension and Capsules. Carolina Pharmaceutical Products. 1988.
12. Co-Principal Investigator. Evaluation of Three Different Immunoassays for Determination of Tobramycin Serum Concentrations. Abbott Laboratories. 1988.
13. Principal Investigator. Evaluation of Theophylline Pharmacokinetic Software in Critically Ill Patients. Abbott Laboratories. 1987.

## MENTORING

---

### Solid Organ Transplantation Specialty Residency

<b>Solid Organ Transplantation Specialty Residency 1996 – 2005</b>		
<b>Year</b>	<b>Resident</b>	<b>Current Position</b>
2004-2005	Matthew Harris	Clinical Specialist in Transplantation, Duke University Medical Center
2003-2004	Derrick Van Beuge	Medical Science Liaison, Bristol Myers Squibb
2002-2003	Ruthann Conoley	Clinical Medical Liaison, Pfizer
2001-2002	Greg Malat	Clinical Specialist in Transplantation, Hahnemann Medical Center
2000-2001	Amy Rosenberg	Residency Director, Shands Hospital UFLA
1999-2000	David Taber	Clinical Specialist in Transplantation, MUSC
1998-1999	Andrea Ciminelli	Buffalo General Hospital
1997-1998	Kimberly Hollar	Medical Science Specialist, Abbott

		Labs
1996-1997	Angela Smith	Duke University Medical Center

### Other Residencies

<b>Other Residents Supervised 1999 – 2010</b>	
<b>Year</b>	<b>Resident</b>
2010	Lisa Fletcher
2010	Chrissy Teeter
2008	Alex Jenkins
2008	Lyndsey Hoffman
2007	Erin McCann
2006	Marintha Meckley
2006	Rocky Karwa
2004	Theresa Thottananiyil
2004	Sabina Ludy
2003	Jill Henderson
2002	Anita Garcia
2002	Jennifer McIntosh
2001	Walid Al-Shaqua
2000	Casey Williams
1999	Imad Treish

### PharmD Clinical Scholars/Honors and Research Elective

<b>Students Supervised on Independent or Honors Research Projects 1999-2012</b>		
<b>Year</b>	<b>Student</b>	<b>Project</b>
2010 – 2012	Thanhhoa Nguyen	Utilization of Mycophenolate Concentrations in Kidney & Liver transplant Recipients
2011 – 2012	Andrea Yuen	UGTs as Biomarkers in Organ Transplantation
2010 – 2011	Jennifer Byrns	Neutropenia in Kidney & Liver Transplant Recipients
2010	Purav Bhatt	Pharmacogenomics of Calcineurin Inhibitors and mTOR inhibitors and Organ Transplantation
2009 – 2010	Tanya Daniels	Cytomegalovirus Prophylaxis in High Risk Liver Transplant Recipients
2009	Tracy Rupp	Survey of North Carolina Pharmacists Utilization of Pharmacokinetic Software

2009	Brian Murray	Vancomycin Dosing Requirements in Morbidly Obese Patients
2008 – 2009	Mike Hurtik	Conversion from Cyclosporine to Tacrolimus
2006 – 2007	James Lagasca	Caffeine Metabolism after Living Donor Liver Transplantation
2006 – 2007	Lisa Bendz	Thymoglobulin and Basiliximab Induction in Liver Transplant Recipients
2006 – 2009	Shazia Ali	UGT1A9 genotype and intestinal metabolism of MPA and Propofol
2005 – 2008	Bridgett Kim	Drug Interaction Study of Piperidine & Mycophenolate
2005 – 2008	Lindsay Jacobs	Comparison of Two Different Valganciclovir Regimens in Kidney & Liver Transplant Recipients
2004 – 2005	Dale Butterfoss	Cyclosporine AUC in Lung Transplant Recipients
2002 – 2004	Kelly Summers	Sirolimus Use in Pediatric Liver Transplant Recipients
2000 – 2002	Mayur Patel	Mycophenolate Pharmacokinetics in Lung Transplant Recipients
2000 – 2001	Kevin Lumbert	Lung Transplantation in Patients in Patients With Cystic Fibrosis
2000 – 2001	Erin Heinzen	Mycophenolate and Antibiotic Drug Interactions
1999 – 2000	Cheryl Reid	Osteoporosis in Liver & Kidney Transplant Recipients

## Fellowship Program

<b>Fellowship Program Primary Advisees 1992 – 2006</b>		
<b>Year</b>	<b>Fellow</b>	<b>Current Position</b>
2006	Kathryn Gillis (TX)	Clinical Research Scientist, Novartis Pharmaceuticals
2004	Eric Williams (DD)	Associate Attorney at Barnes & Thornburg LLP
2002	Andrew Nelsen (DD)	United Therapeutics
2001	Kevin Haynes (DD)	Senior Research Investigator, School of Medicine, University of Pennsylvania
1998	Odin Naderer (DD)	Director, Infectious Diseases, Discovery Medicine, GlaxoSmithKline
1997	Kimberly Hollar (TX)	Clinical Science Manager in Virology, Abbott Laboratories
1997	Kimberly Parnell (DD)	Associate Director, Clinical Research, Johnson & Johnson, Pharmaceutical Research & Development
1996	Benjamin Lee (DD)	(no information)
1995	Patrick Wire (PK)	Director, Global Regulatory Affairs at GlaxoSmithKline
1992	Jorge Miranda (PK)	Professor, School of Pharmacy, University of Puerto Rico

\*DD = Drug Development; PK = Pharmacokinetics; TX = Transplantation

### Graduate Program – Dissertation (D) or Student (S) Advisory Committees

2014 – present	Jason Slizgi (S)
2012 – 2013	Brandon Gufford (S/D) - Chair
2006 – 2013	Christina Won (S/D)
2007 – 2012	Latoya Poole-Griffin (S/D)
2002 - 2006	Melanie Tallman (D)
2003 – 2008	Emily Olson (D)

### EDITORIAL SERVICE

---

#### Review Board Member

Pharmacotherapy (Editorial Board) 2009 – present  
Annals of Pharmacotherapy (Editorial Board - Transplant section) 2003 – 2014

#### Reviewer and Contributor

Therapeutic Drug Monitoring 2011 – present  
Current Opinions in Molecular Therapeutics 2011  
ASHP PharmPrep 2005 – present  
PSAP Clinical Algorithms Handbook 2000-2003  
Journal of Pharmacy Practice 1999-2002  
Pharmacotherapy Self-Assessment Program (PSAP) 1999-2000; 2007  
American Journal of Pharmaceutical Education 1998 – 1999  
Renal Failure 1991 – 1994  
American Journal of Health Systems Pharmacists 1990  
Archives of Pathology 1989 – 1999  
Clinical Chemistry 1993 – 1994  
Pharmacotherapy Specialty Board 1992 – 1993  
NCTRACS Grants PILOT Program 2009

### ADVISORY BOARDS

---

#### Industry

2012	Novartis Pharmaceuticals
2011	Kaletra Health
2010	Abbott Laboratories/ Abbvie Inc
2009	Novartis Pharmaceuticals
2006	Nabi Biopharmaceuticals
2004 – 2008	Astellas/ Fujisawa Pharmaceuticals
2004	Genzyme Inc
1999 – 2001	Roche Inc
2000	Wyeth-Ayerst Pharmaceuticals
1999	Sidmak Inc.
1998	Sangstat Inc.
1997 – 2003	Astellas/ Fujisawa Pharmaceuticals

#### Food and Drug Administration

2008 – present Cardio-Renal Advisory Panel, ad hoc member

#### Drug Safety and Monitoring Boards

2012 – present            UNC Food Allergy and Immunotherapy Studies – Dr Wesley Burks PI

2013 – present            Treatment of HCV Post Liver Transplant Study – Abbvie Inc

## **COMMITTEE APPOINTMENTS**

---

AST Community of Pharmacists Transplant Organ Donation Awareness Committee 2009-present  
NIH Adult to Adult Living Donor Liver Transplant Consortium Liver Regeneration Subcommittee 2002 - present  
ACCP Fellowship Committee 2012 – present  
UNC School of Pharmacy Admissions Committee 2014 - present  
UNC School of Pharmacy Curricular Transformation Oversight Committee 2013- present  
UNC DPET Assistant/Associate Professor Search Committee (Chair) 2014 - present  
UNC School of Pharmacy Scholarship Committee 2011- present  
UNC DPET Pharmacometrics Program Committee 2010-2012  
UNC School of Pharmacy Honors Committee 1999- present (Chair, co-Chair, member)  
UNC RhoChi Faculty Advisor 2006 – present  
UNC Student Industry Interest Group Faculty Advisor– 2008- present  
UNC DPET Fellowship Committee, Director/Chair 2006 – present  
UNC Renovations Committee 2011-present  
UNC/UNCH Partnership in Patient Care Acute Care Committee 2011  
UNC School of Pharmacy ACPE Accreditation Committee 2010-2011  
UNC DPEE Clinical Assistant Professor Search Committee 2010-2011  
UNC Healthcare Systems Transplant Outcomes QuaPI Committee 2006- 2012  
UNC MSCR UNC-Wilmington New Degree Program Committee 2009  
UNC DPET Assistant Professor Search Committee 2007  
UNC DPET Clinical Pharmacology Search Committee (Chair ) 2008  
UNC DPET Graduate Student PhD Committees 2008-present  
UNC School of Pharmacy PharmD/PhD Committee 2007 - 2008  
UNC School of Pharmacy Faculty Salary Committee 2002 – 2008  
UNC School of Pharmacy Admissions and Recruitment Committee 2007 – 2010  
UNC Faculty Council 2005 – 2008  
UNC School of Pharmacy Scholarship & Awards Committee 1999-2008  
UNC DPET Promotion and Reappointment Committee 2002 – 2008  
UNC Graduate Student Advisory PhD Committee DPET and MOPH 2002-2006  
UNC Graduate Student Advisory PhD Committee DPET and MOPH 2006-2008  
UNC Graduate Student Advisory Master's Committee DPET & Division of MOPH 1987– 2003  
UNC School of Pharmacy Faculty Development Committee, 1993 – 1998  
UNC Ferguson Lecturer Committee (chair) 95-97  
ACCP Research Affairs Committee 2008- 2010  
ACCP Immunology/ Transplant Program Committee 2001  
ACCP Clinical Affairs Committee, 1998 - 2000  
ASHP Immunology/ImmunoTherapeutics Fellowship Committee, 1996 – 2000  
ACCP Industrial Relations Committee, 1996 – 1997

## **PROFESSIONAL SOCIETY MEMBERSHIPS**

---

American College of Clinical Pharmacy  
American Society of Health-System Pharmacy  
American Society of Transplantation  
Triangle Chapter of the American College of Clinical Pharmacy